A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society

Jenny E Gunton, N Wah Cheung, Timothy M E Davis, Sophia Zoungas and Stephen Colagiuri
Med J Aust 2014; 201 (11): 650-653. || doi: 10.5694/mja14.01187


  • Lowering blood glucose levels in people with type 2 diabetes has clear benefits for preventing microvascular complications and potential benefits for reducing macrovascular complications and death.
  • Treatment needs to be individualised for each person with diabetes. This should start with selecting appropriate glucose and glycated haemoglobin targets, taking into account life expectancy and the patient's wishes. For most people, early use of glucose-lowering therapies is warranted.
  • A range of recently available therapies has added to the options for lowering glucose levels, but this has made the clinical pathway for treating diabetes more complicated.
  • This position statement from the Australian Diabetes Society outlines the risks, benefits and costs of the available therapies and suggests a treatment algorithm incorporating the older and newer agents.

Please login with your free MJA account to view this article in full

  • Jenny E Gunton1
  • N Wah Cheung2
  • Timothy M E Davis3
  • Sophia Zoungas4
  • Stephen Colagiuri5

  • 1 Western Clinical School, University of Sydney, Sydney, NSW.
  • 2 Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, NSW.
  • 3 School of Medicine and Pharmacology, University of Western Australia, Perth, WA.
  • 4 Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC.
  • 5 Boden Institute of Obesity, Nutrition, Exercise and Eating Disorders, University of Sydney, Sydney, NSW.


We thank Jennifer Conn and Merryl Koschade for help with reformatting the treatment algorithm, and the ADS membership for their comments on the position statement.

Competing interests:

Jenny Gunton is a member of the Pharmaceutical Benefits Advisory Committee. She received speakership honoraria for two Novo Nordisk-sponsored meetings with independent program organising committees in 2012–13. Wah Cheung has received a speakership honorarium from the Chinese Endocrine Society, which was provided by Sanofi. Timothy Davis has served on advisory boards for and received research funding, speaker fees and travel assistance to attend meetings from Merck Sharp & Dohme, Novartis, Novo Nordisk and Sanofi Aventis; has served on advisory boards for and received speaker fees and travel assistance to attend meetings from AstraZeneca and Boehringer Ingelheim; and has served on advisory boards for and received research funding and speaker fees from Takeda. Sophia Zoungas has served on advisory boards for Amgen Australia, AstraZeneca/Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Sanofi and Takeda; has received consultancy fees and honoraria from AstraZeneca/Bristol-Myers Squibb, Janssen-Cilag, Merck Sharp & Dohme and Servier; and has conducted institutional contract work for Bristol-Myers Squibb. Over the past 3 years, Stephen Colagiuri sat on advisory boards for and/or received speaking fees from AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Medtronics, Novartis, Novo Nordisk, Sanofi Aventis, Servier and Takeda.

  • 1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
  • 2. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
  • 3. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772.
  • 4. Cheung NW, Conn JJ, d'Emden MC, et al. Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Med J Aust 2009; 191: 339-344. <MJA full text>
  • 5. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103: 491-497.
  • 6. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996; 44: 751-755.
  • 7. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997; 50: 735-741.
  • 8. Gerich J, Raskin P, Jean-Louis L, et al. PRESERVE-β: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005; 28: 2093-2099.
  • 9. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012; 34: 1247-1258.e22.
  • 10. Meier JJ, Nauck MA. Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia 2014; 57: 1320-1324.
  • 11. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab 2012; 23: 205-215.
  • 12. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36: 2508-2515.
  • 13. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011; 28: 1352-1361.
  • 14. Roberts VL, Stewart J, Issa M, et al. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2005; 27: 1535-1547.
  • 15. Derosa G, Salvadeo SA, D'Angelo A, et al. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr Med Res Opin 2009; 25: 607-615.
  • 16. Scheen AJ. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Diabetes Metab 1998; 24: 311-320.
  • 17. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
  • 18. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50: 259-267.
  • 19. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-2055.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.